Anis Hamid, MBBS

home / authors / anis-hamid-mbbs

Articles

Dr. Hamid on Potential Combinations With Docetaxel in mHSPC Subtypes

Dr. Hamid on Potential Combinations With Docetaxel in mHSPC Subtypes

Anis Hamid, MBBS
April 30th 2020

Anis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.

Read More

Dr. Hamid on Next Steps for Precision Medicine in mHSPC

Dr. Hamid on Next Steps for Precision Medicine in mHSPC

Anis Hamid, MBBS
April 24th 2020

Anis Hamid, MBBS, discusses next steps for precision medicine in metastatic hormone sensitive prostate cancer.

Read More

Dr. Hamid on the Evolution of Precision Medicine in Prostate Cancer

Dr. Hamid on the Evolution of Precision Medicine in Prostate Cancer

Anis Hamid, MBBS
April 3rd 2020

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

Read More

Dr. Hamid on the Exploration of Predictive Biomarkers in mHSPC Subtypes

Dr. Hamid on the Exploration of Predictive Biomarkers in mHSPC Subtypes

Anis Hamid, MBBS
March 20th 2020

Anis Hamid, MBBS, discusses the hypothesis of predictive biomarkers for newly diagnosed metastatic hormone sensitive prostate cancer.

Read More

Dr. Hamid on the Progression of Therapy for Metastatic Prostate Cancer

Dr. Hamid on the Progression of Therapy for Metastatic Prostate Cancer

Anis Hamid, MBBS
March 17th 2020

Anis Hamid, MBBS, discusses the progression of therapy for metastatic prostate cancer.

Read More

Dr. Hamid on a Potential Biomarker of Response to Docetaxel in mHSPC

Dr. Hamid on a Potential Biomarker of Response to Docetaxel in mHSPC

Anis Hamid, MBBS
February 25th 2020

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the potential predictive value of the luminal B subtype as a biomarker of response to docetaxel in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need